EUVIMEDEUVIMED entdecken
Crossref

2394-P: Integration of Diabetes Genetics into Clinical Practice

LIANA K. BILLINGS, ELENA S. GROSS, SHANNAH MWANDA, MOHAMMAD R. SALAH, ANNABELLE ASHWORTH, EMILY FUNG, ATHANASIOS KONDILIS, MAYA RAVIV, ZHUQING SHI, JIANFENG XU

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2394-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LIANA K. BILLINGS und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Despite increasing evidence that genetic testing can inform diabetes type, prognosis, and treatment, its clinical use remains limited. Since 2016, we established the Personalized Medicine in Diabetes Clinic (PMDC) to integrate diabetes genetic testing into practice. The clinic serves as a referral center for patients with atypical diabetes.

Methods

PMDC-referred patients were evaluated by a clinician, received genetic counseling and testing, and had results reviewed. CLIA-certified testing was performed using the GeneDx MODY Panel (5 or 16 MODY genes) until 2021, GoPath Diagnostics DiabetesNOW 1.0 (17 MODY genes, T1D/T2D polygenic risk score [PRS]) until 2024, followed by DiabetesNOW 2.0 (18 monogenic diabetes genes, pan-ancestry T1D/T2D PRS).

Results

PMDC patients (n=112) were 33% male, 69.6% Caucasian, mean BMI 24.7 ± 6.2 and age 38.9 ± 19.8; 13.3%, 42%, 21.4%, and 24.1% had T1D, T2D, prediabetes, and gestational diabetes, respectively. Genetic testing identified monogenic diabetes variants in 47 patients (26 GCK, 5 HNF1A, 3 HNF4A, 1 HNF1B, 2 INS, 2 INSR, 3 WFS1, and 7 other), 60% of which were pathogenic/likely pathogenic. Additionally, 11.1% had a relative T1D risk >2.0 by PRS and showed features more consistent with T1D than lower-risk patients. Results are shown in Table 3.

Conclusion

Over ten years, we demonstrate the feasibility and clinical impact of integrating diabetes genetics into clinical care using a single-clinician model and a novel genetic panel. Disclosure L.K. Billings: Advisory Panel; Current; Novo Nordisk, Lilly, Sanofi, Amgen Inc., Bayer AG. E.S. Gross: None. S. Mwanda: None. M.R. Salah: None. A. Ashworth: None. E. Fung: None. A. Kondilis: None. M. Raviv: None. Z. Shi: Consultant; Current; GoPath. J. Xu: Advisory Panel; Current; GenomicMD, GoPath Labs.

Zitieren

APA

BILLINGS, L. K., GROSS, E. S., MWANDA, S., SALAH, M. R., ASHWORTH, A., FUNG, E., KONDILIS, A., RAVIV, M., SHI, Z., & XU, J. (2026). 2394-P: Integration of Diabetes Genetics into Clinical Practice. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2394-p

Vancouver

BILLINGS LK, GROSS ES, MWANDA S, SALAH MR, ASHWORTH A, FUNG E, et al. 2394-P: Integration of Diabetes Genetics into Clinical Practice. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2394-p

BibTeX
@article{BILLINGS2026,
  author = {BILLINGS, LIANA K. and GROSS, ELENA S. and MWANDA, SHANNAH and SALAH, MOHAMMAD R. and ASHWORTH, ANNABELLE and FUNG, EMILY and KONDILIS, ATHANASIOS and RAVIV, MAYA and SHI, ZHUQING and XU, JIANFENG},
  title = {2394-P: Integration of Diabetes Genetics into Clinical Practice},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2394-p}
}
Kostenlos starten →